Efficacy and safety analysis of different treatment schemes of erythropoiesis-stimulating agents for chronic kidney disease with anemia: a meta analysis between 2000-2024.

1 Mean difference −0.62 × 10 − 3 (95% CI −1.25 to 0.01) × 10 − 3 , p = 0.06, indicating a borderline significant trend favoring darbepoetin; Fig. 2 Mean difference −0.83 × 10 − 3 (95% CI −1.46 to −0.19) × 10 − 3 , p = 0.01, demonstrating a statistically significant advantage for darbepoetin Fig. 3 Mean difference −1.45 × 10 − 3 (95% CI −2.06 to −0.83) × 10 − 3 , p < 0.00001, indicating a highly significant superiority of darbepoetin Collectively, these findings suggest that, under most study conditions, darbepoetin is likely to be more effective than short-acting epoetin in achieving or maintaining target hemoglobin concentrations.

also in 64 other papers

641 participants) showed a marginal trend favoring the low-frequency, high-dose regimen (mean difference [MD] = 1.62 g/L, 95% confidence interval [CI] −0.62 to 3.87); however, the confidence interval crossed zero, indicating that the difference was not statistically significant ( p = 0.16).

also in 269 other papers

3 Mean difference −1.45 × 10 − 3 (95% CI −2.06 to −0.83) × 10 − 3 , p < 0.00001, indicating a highly significant superiority of darbepoetin Collectively, these findings suggest that, under most study conditions, darbepoetin is likely to be more effective than short-acting epoetin in achieving or maintaining target hemoglobin concentrations.

also in 42,942 other papers